LUNGPulmonx Corp.

Pulmonx (NASDAQ:LUNG) is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat. French, who

Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.

Net loss narrowed to $10.1 million as cost cuts offset China suspension.

Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Moby summary of Pulmonx Corporation's Q2 2026 earnings call

Pulmonx (NASDAQ:LUNG) reported second-quarter revenue of $22.8 million and reiterated its full-year 2026 revenue outlook, while executives highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses and preparing to resume shipments to China. Revenue for the quarter

Pulmonx (LUNG) delivered earnings and revenue surprises of +14.29% and +2.34%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.

Moby summary of Pulmonx Corporation's Q1 2026 earnings call

Pulmonx Corp (LUNG) demonstrates resilience with operational momentum and strategic expansion despite revenue challenges.